Hospira Recalls Propofol Injectable Vials Due to Particulate Matter
Hospira Inc. is recalling 56,420 vials of Propofol Injectable Emulsion because a visible particulate was found during inspection.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves particulate matter in an injectable drug. While Class II recalls are generally moderate, the specific finding of a single visible particulate in a sample bottle during inspection, without reported injuries or deaths, aligns with the criteria for a moderate severity score involving low-risk contamination or voluntary precautionary measures.
Plain-English summary
Hospira Inc. is recalling 56,420 vials of Propofol Injectable Emulsion, 1%, 1 g/100 mL (10 mg/mL), 100 ml Single patient infusion vial. The recall is due to the presence of particulate matter, specifically a single visible particulate that was observed and confirmed in a sample bottle during retain inspection.
The affected product is distributed nationwide. The specific lot codes involved are 07-893-DJ (exp. 7/2013), 10-123-DJ, and 10-125-DJ (exp. 10/2013). The product is a prescription-only medication used for general anesthesia.
Healthcare providers and patients should check their inventory for these specific lot codes and expiration dates. If the product is found, it should be quarantined and not administered. Hospira Inc. is the recalling firm.
The recalled product
- Product
- PROPOFOL (PROPOFOL)
- Brand
- PROPOFOL
- Manufacturer
- Hospira Inc.
- Category
- Drug — Injectable Anesthetic
- Hazard
- Affected units
- 56,420
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- 07-893-DJ
- exp. 7/2013
- 10-123-DJ
- 10-125-DJ
- exp. 10/2013
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · PROPOFOL
- CriticalPropofol Injectable Emulsion Recalled for Particulate Matter Contamination
FDA (Drugs) · 2022-09-21
- SeverePropofol Injectable Emulsion Vials Recalled for Particulate Matter Contamination
FDA (Drugs) · 2022-08-03
- SevereHospira Recalls Propofol Injectable Emulsion Due to Temperature Excursions
FDA (Drugs) · 2015-02-25
- SevereHospira Recalls Propofol Injectable Vials Due to Embedded Particulate Matter
FDA (Drugs) · 2015-02-04
- SevereHospira Recalls Propofol Vials Due to Metallic Particulate Matter
FDA (Drugs) · 2014-08-27
Same manufacturer · Hospira Inc.
See all →- CriticalHospira Recalls Dextrose Injection Syringes Due to Human Hair Particulate
FDA (Drugs) · 2017-05-31
- ModerateHospira Recalls Minibore Extension Sets Due to Solvent Occlusion
FDA (Devices) · 2017-01-18
- LowHospira Recalls Lidocaine and Dextrose Injection for Stability Failures
FDA (Drugs) · 2016-12-14
- SevereHospira Recalls Fentanyl Citrate Injection Ampules Due to Broken Tips
FDA (Drugs) · 2016-11-30
- HighHospira Symbiq Infusion Pump Recall for White Screen Safety Shutdown
FDA (Devices) · 2016-11-16
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26